With vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the capacity to make them at scale, as new deals for BioNTech and Eli Lilly this week ...

Robert F. Kennedy — a vaccine critic, obesity-drug skeptic and processed-foods hater — has secured his spot as head of the US ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Eli Lilly investors and analysts said they ... citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi ...

Healthcare sector shows strong performance in January amid signs of a brighter 2025, according to analysts. Read more here.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Since 2023, there has been rapid growth in the market ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Learn More » Pfizer (NYSE: PFE) stood out a few years ago thanks to its coronavirus products and ... that value investors won't want to miss. Eli Lilly (NYSE: LLY) sells a broad variety of ...